Utility of TLE1 immunohistochemistry in melanoma

Background: TLE1 immunohistochemistry (IHC) is widely used as a biomarker of synovial sarcoma. Recently, we described moderate to strong TLE1 expression in 57% of dermal spindle cell melanomas with an additional 33% with weak expression. The utility of TLE1 IHC in melanoma has not been well described. The aim of this study was to investigate TLE1 expression in melanoma.